MedTrace Logo

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2008-03-05

No results posted yet for this study

Summary

The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.

Conditions

  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Sezary Syndrome

Interventions

DRUG

ONTAK

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Elyane Lombardy, M.D. · Ligand Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-06-30
Primary Completion
2006-09-30
Completion
2006-12-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • Germany
  • Netherlands
  • Poland
  • Russia
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050999 on ClinicalTrials.gov